Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025
Structure Therapeutics (NASDAQ: GPCR) will release topline data from its ACCESS clinical program of aleniglipron, a once-daily oral small-molecule GLP-1 receptor agonist for obesity, before market open on Monday, December 8, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Structure Therapeutics (NASDAQ: GPCR) will release topline data from its ACCESS clinical program of aleniglipron, a once-daily oral small-molecule GLP-1 receptor agonist for obesity, before market open on Monday, December 8, 2025. Management will host a conference call and webcast to discuss the data at 8:30 a.m. ET the same day.
Investors can access the live webcast via the company Investor Relations events page and obtain phone dial-in details from the provided link. A replay will be posted approximately two hours after the live event and will remain available for 90 days.
Details
News Market Reaction – GPCR
On Dec 8, the first trading day after this news, GPCR closed 102.49% above the previous close.
Data tracked by StockTitan Argus for the Dec 8 session.
Key Figures
- Topline data date
- December 8, 2025
- ACCESS aleniglipron clinical program readout before market open
- Conference call time
- 8:30 a.m. ET
- Management call to discuss ACCESS topline data
- Webcast replay length
- 90 days
- Replay availability on company investor relations website
Historical Context
-
Reaffirmed ACCESS data timing and strong cash balance through at least 2027.
-
Announced participation in major healthcare investor conferences with webcasts.
-
Higher R&D spend and larger net loss while advancing oral obesity pipeline.
-
New preclinical data for oral amylin agonist and GLP-1 candidate at ADA meeting.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
glp-1 receptor agonist medical
topline data technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced plans to release topline data from its ACCESS clinical program of aleniglipron, the company’s once-daily oral small molecule GLP-1 receptor agonist for the treatment of obesity, before the market opens on Monday, December 8, 2025. Members of management will host a conference call and webcast to discuss the data at 8:30 a.m. ET the same day.
To access the live webcast, please visit the Investor Relations page of the company’s website at https://ir.structuretx.com/events-presentations/events. To access the call by phone, participants should visit this link to receive dial-in details. The webcast will be made available for replay on the company's website beginning approximately two hours after the live event. The replay of the webcast will be available for 90 days.
About Structure Therapeutics
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more people living with obesity around the world. For additional information, please visit www.structuretx.com.
Investors:
Danielle Keatley
Structure Therapeutics Inc.
ir@structuretx.com
Media:
Dan Budwick
1AB
Dan@1abmedia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.